About the Authors
- Alexander Y. Deneka
-
* E-mail: Erica.Golemis@fccc.edu (EG); Alexander.Deneka@fccc.edu (AD)
Affiliations Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America, Department of Biochemistry, Kazan Federal University, Kazan, Russia
- Leora Haber
-
Affiliation Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America
- Meghan C. Kopp
-
Affiliations Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America, Program in Molecular and Cell Biology and Genetics, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America
- Anna V. Gaponova
-
Affiliations Laboratory of Genome Engineering, Moscow Institute of Physics and Technology, Dolgoprudny, Russia, Immanuel Kant Baltic Federal University, Konigsberg, Russia
- Anna S. Nikonova
-
Affiliation Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America
- Erica A. Golemis
-
* E-mail: Erica.Golemis@fccc.edu (EG); Alexander.Deneka@fccc.edu (AD)
Affiliation Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America
Competing Interests
David Proia and Synta Pharmaceuticals provided STA- 8666 for this study but no funding. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceptualization: EG AD AN. Funding acquisition: EG. Investigation: AD LH AG AN MK. Methodology: EG AD AN AG. Project administration: EG AD. Resources: AN AD. Supervision: EG. Validation: EG AD. Visualization: AD. Writing – original draft: AD. Writing – review & editing: AD EG.